Ex-GSK, Novartis exec named as Mundipharma’s Head of Access
Mundipharma has announced that Jerome Moreau has joined the company as its new Head of Market Access.
Moreau has amassed experience in a range roles focusing on sales and marketing and later management and business development during his 25 years of experience in the pharma and biotechnology industry.
Most recently, he worked at GlaxoSmithKline as its Director, Global Market Access and Pricing. In the role, he was responsible for crafting and enacting a global strategy for access and pricing across the COPD franchise and local operating companies.
Prior to that role, Moreau served as Senior Expert of Strategic Operations, Market Access & Public Affairs at Novartis in France. In that position, he led the company’s market access and public affairs strategy.
In his new role at Mundipharma, Moreau will report to Chris Surridge, European Director of Strategy and Commercial Excellence.
Surridge commented: “With a proven track record in the market access arena, Jerome has set out clear goals of how he will help to shape, inspire, and enhance our market access capabilities at Mundipharma. We share his view that market access should be closely aligned to business priorities, creating value at every point of the patient journey. This emphasis on building trust through early, robust, credible and meaningful engagement with payers aligns with our focus on delivering innovation and commercial excellence through partnerships.”
Commenting on his appoint, Moreau said: “It’s the unique size, culture and decentralised business model at Mundipharma that inspired me to join the team. I am focused on developing the market access function to become a benchmark in the industry and ensuring it is integrated in everything we do. Mundipharma will enable me to deliver this vision and it is the ideal organisation in which to further expand my breadth of experience and passion for patient access.”
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …